Eye drops, eye ointment and method for treatment of ophthalmology diseases

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: treatment of ophthalmology diseases by administration in conjunctival sac of patient eye as well as injection of medicine, in particular alkali salt of 5-amino-2,3-dihydro-1,4-phtalasindione is disclosed. Eye drops, eye ointment contain alkali salts of 5-amino-2,3-dihydro-1,4-phtalasindione or mixture thereof, wherein lithium or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phtalasindione is selected as alkali salt, and mixture of above mentioned salt in equal ratio is used as mixture salts of 5-amino-2,3-dihydro-1,4-phtalasindione.

EFFECT: treatment method with improved effectiveness and reduced treatment duration.

16 cl, 6 ex

 

The invention relates to medicine, namely to ophthalmology, and can be used for the treatment and prevention of eye diseases of different nosology.

There is a method of treatment of eye diseases, comprising the administration to the patient of the drug sulfacetamide by or/and putting in into the conjunctival eye bag 1-2 drops 3 times a day (10-30)% aqueous solution of the drug, and/or lubrication of the affected organ corresponding ointment composition, or/and dusting, for example, cornea powder of this drug, and its ingestion (see, for example, Medmaravis “drugs”. Ed. “Medicine”, M, 1985, Vol.2, SS-282).

A known method is used in the treatment of conjunctivitis, blepharitis, purulent ulcerations of the cornea, as well as with gonorrheal eye infections in newborns and adults, and other infectious diseases of the eye. However, such treatment is not indicated for patients with toxic-allergic reactions to sulfonamides, diseases of the haematopoietic system and uremia.

The closest analogue prototype is a method of treatment of eye diseases, including the introduction of a medicinal product containing salt (iodine) alkali metals potassium - “Potassium iodide or sodium “Sodium iodide” by putting in into the conjunctival eye bag PAC is enta 1 drop 3 times a day 3% aqueous solution of the drug (see, for example, Medmaravis “drugs”, Ed. “Medicine”, M, 1985, Vol.2, SS-133).

This method is used in the treatment of cataracts in the late syphilitic changes of the optic nerve (Sodium iodide) and other eye diseases, however, it is contraindicated in idiosyncrasy to iodine.

Known eye drops made in the form of (10-30)% aqueous solution of the drug sulfacetamide (see, for example, Medmaravis “drugs”, Ed. “Medicine”, M, 1985, Vol.2, s-282).

These drops are used to treat conjunctivitis, blepharitis, purulent ulcerations of the cornea, as well as with gonorrheal eye infections in newborns and adults, and other infectious diseases of the eye. However, they are contraindicated in patients with toxic-allergic reactions to sulfonamides, diseases of the haematopoietic system and uremia, and in addition, the use of these drops in the form of a more concentrated solution causes irritation of the tissues.

The closest analogue of the prototype are eye drops containing 3% aqueous salt solution (potassium iodide) alkali metals potassium -“Potassium iodide or sodium “Sodium iodide” (see, for example, Medmaravis “drugs”. Ed. “Medicine”, M, 1985, Vol.2, SS-133).

These drops are used in the treatment of cataracts and other eye diseases, one of the ako they are contraindicated in idiosyncrasy to iodine.

Known ointment containing (10-30)% of the drug sulfacetamide” on wax basis (see, for example, Medmaravis “drugs”. Ed. “Medicine”, M, 1985, Vol.2, SS-282).

This ointment is used to treat conjunctivitis, blepharitis, purulent ulcerations of the cornea, as well as with gonorrheal eye infections in newborns and adults, and other infectious diseases of the eye. However, its use is contraindicated in patients with toxic-allergic reactions to sulfonamides, diseases of the haematopoietic system and uremia.

The closest analogue prototype is 0.5% eye ointment hydrocortisone (Unguentum hydrocortisone acetates 0,5%), 2.5 g containing 0.0125 g of hydrocortisone acetate and 0.005 g of chloramphenicol (chloramphenicol) (see, for example, Medmaravis “drugs”. Ed. “Medicine”, M, 1985, vol. 1, s).

This ointment is used to treat conjunctivitis, blepharitis, IRITO, keratitis and other, but it is contraindicated in case of viral and fungal diseases of the eye and the eye of tuberculosis.

The present invention solves the problem of obtaining a treatment for the spectrum of eye diseases, and eye drops and eye ointment for carrying out the method without constraints on their use through any contraindications.

The invention is what is in the way of treatment of eye diseases, includes introduction to the conjunctival SAC of the eye of the patient a medicinal product in the form of alkaline salts, when treatment is also the rate of injection of the patient, with the introduction of a medicinal product produced (1-5) times per day, the rate of injection fulfill containing (10-25) injection, and the injection of exercise (1-2) times a day or 1 time a day, and for injection use alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, while a single dose for injection are chosen number (20-2000) mg alkaline salt or mixture alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione on (1-10) ml of water for injection.

At the same time as alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione choose or lithium, or sodium, or potassium, or calcium salt and as a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione use is composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

In addition, the at as a medicinal product for introduction into the conjunctival SAC of the eyes of the patient or for injection lithium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or choose for injection or lithium, or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

When choosing a medicinal product for introduction into the conjunctival SAC of the eye patientely for injection sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or incorporating into the conjunctival SAC of the eye of the patient to choose or sodium, or lithium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium or potassium and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-Digi the ro-1,4-phthalazinedione.

Selecting as a medicinal product for introduction into the conjunctival SAC of the eyes of the patient or for injection of the potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or incorporating into the conjunctival SAC of the eye of the patient to choose or potassium, or lithium, or sodium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Selecting as a medicinal product for introduction into the conjunctival SAC of the eyes of the patient or for injection of the calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or incorporating into the conjunctival SAC of the eye of the patient to choose or calcium, or lithium, or sodium, or potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium, calc the eve or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

This introduction to the conjunctival SAC of the eye of the patient medication exercise and/or by putting the appropriate eye drops, or/and lubrication of the conjunctiva of the corresponding eye ointment or dusting of the cornea powder drug.

The essence of the invention lies in the fact that eye drops containing an aqueous solution of alkaline salts, the use of alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, in the following ratio of the components.%: alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 0,1-10,0; water - the rest.

At the same time as alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione in use or lithium, or sodium, or potassium, or calcium salt and as a mixture of alkaline salts choose is composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or kleevage calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

The invention consists in that eye ointment containing pharmaceutical preparation in the form of alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione ointment on the basis that includes a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione and ointment base is made in the form, for example, medical vaseline, in the following ratio of components, wt.%: alkaline salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0-50,0; vaseline medical - rest.

At the same time as alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione use it or lithium, or sodium, or potassium, or calcium salt and as a mixture of alkaline salts choose is composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-falasi is Dion.

In addition, when the dusting of the cornea as drug use or lithium, or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or mixtures of these salts, or of parts of these salts.

When choosing or for injection or eye drops or eye ointment or dusting of the cornea to the lithium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting of the cornea, either lithium or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Also when choosing or for injection or eye drops or eye ointment or dusting of the cornea sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, inpart of eye drops, as part of eye ointments, dusting cornea choose or sodium, or lithium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

When choosing or for injection or eye drops or eye ointment or dusting of the cornea of the potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting cornea choose or potassium, or lithium, or sodium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or nutria is Oh, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

In addition, when choosing or for injection or eye drops or eye ointment or dusting of the cornea of the calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting cornea choose or calcium, or lithium, or sodium, or potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Studies have shown that this method of treatment of eye diseases due to bifurcation activity used drug in inflammatory processes selectively, for a few hours inhibits the activity of macrophages, reducing accordingly the level of TNF and ostrofsky proteins, which leads to smoothing of the symptoms of intoxica the AI. When this happens enhanced superoxidedismutase function and phagocytic activity of neutrophils and the corresponding strengthening of microbicide system cells and the relief of the inflammatory process.

When weak response cellular immunity, for example, in the presence of malignant tumors of the proposed method of treatment due to the introduction of a medicinal product of an alkaline salt or mixture of alkali salts of 5-amino-2,3-dihydro-1,4-phthalazinedione provides the release of TNF (tumor necrosis factor, interleukins and other ostrofsky proteins, indicating that the activation of macrophages. At the same time also specifically react to the introduction of a drug T-lymphocytes.

Studies have shown that injected into a patient by injection or other means the drug in the form of alkali (for example, lithium or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione (chemical formula accordingly - C8H6N3About2Li, or C8H6N3About2Na or C8H6N3About2K or (C8H6N3About2)2Sa) or mixtures of these alkaline salts of this salt (mixture of salts) is divided into metal cations (respectively Li+, Na+K+or Sa+) and anions 5-amino-hydro-1,4-phthalazinedione (respectively 8H6N3On

-
2
). However cations fill the needs of the body, and anions interacting, for example, blood plasma, disintegrate emitting carbon, atomic oxygen, nitrogen and hydroxyl group (OH). Then oxygen and nitrogen are recovered, thereby setting the antioxidant activity and hydroxyl groups interact with carbon, translating KHS from a state of acidosis in the alkaline side.

In addition, due to the presence of the chemiluminescent properties lyuminola on the basis of which formed the drug, under oxidative reactions with lyuminola (with the anion of 5-amino-3-hydro-1,4-phthalazinedione) is the emission of light energy (see also, for example, http:// www.gpo.ucop.edu, Briheim et al., 1984), and in the interaction with albumin increased intensity of chemiluminescence proportional to the increase in the concentration of albumin (see ibid., Buturlakin et al, 1975).

Studies have shown that the emission of light energy by chemiluminescence is perceived by the cells of the body, and the emitted when the quanta of light energy are involved in the mechanism of exchange as contributing to the process of exchange of energy supply.

Research is also provided, what if the changed condition of the membrane (cytoplasm) of the cell (which is a consequence of many diseases) introduction drug alkali metal salts or mixtures of these salts lyuminola causes the membrane in the normal state, normalizes and regulates inside and intercellular metabolic processes and therefore normalizes metabolism.

The invention is confirmed by the examples.

Example 1.

Patient S., 18 years.

Complaints about eye fatigue when reading and computer work, the feeling of sand in eyes.

Turning redness of the conjunctiva, the mucous.

Diagnosis: chronic conjunctivitis.

A course of treatment: daily for 10 days intramuscularly injection of sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 100 mg per 1 ml of water for injection and instillation in the eye with eye drops containing 2% aqueous solution of sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, one drop in the morning and afternoon and lubrication of the conjunctiva before sleep eye ointment containing 5% of sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione.

After the treatment the condition is satisfactory, the recommended backfill within 7 days once in the morning, eye drops containing 5% aqueous solution of a mixture in equal proportions of sodium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Example 2.

Patient G, a graduate student, 23 years.

Complaints of itching in the eyes, photophobia, fatigue when reading.

When contacting the redness and ulceration of the edges of the eyelids, slime.

History of recently migrated shingles.

Diagnosis: ulcerative blepharitis.

A course of treatment: daily for 10 days intramuscular injection of a mixture of lithium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 150 mg (in a ratio of lithium and sodium salts of 1:2) to 2 ml of water for injection and lubrication in the morning and in the evening of the conjunctiva of the eye with an ointment containing 10% potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, and dusting of the cornea before sleep powder the calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione.

After the course is positive, the condition is satisfactory, appointed continued for 5 days procedures lubrication of the conjunctiva of the eye ointment former staff and dusting of the cornea, but the corresponding potassium salt.

Two weeks after the start of treatment ulceration and redness of the eyelids is not observed, no itching, fatigue when working with books has decreased slightly. However, after prolonged use with a computer, you receive the redness of the eyelids.

Recommended for (5-7) days to continue the lubrication of the conjunctiva before bedtime GLA is Noah ointment, containing 5% of sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Example 3.

Patient E., 20 year.

Complaints about itchy eyes during and after contact lens wear.

When contacting the inflammation of the cornea and presumably the iris of the left eye.

The diagnosis of conjunctivitis, iridia.

A course of treatment: daily for 7 days injection: intraocular - lithium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 50 mg per 1 ml of water for injection and intramuscular injection of a mixture of lithium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 100 mg (in a ratio of lithium and sodium salts of 1:1) 1 ml of water for injection and lubrication in the morning and in the evening of the conjunctiva of the eye with an ointment containing 5% potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione.

After the course is satisfactory, scheduled to continue for 5 days lubrication in the morning and in the evening of the conjunctiva of the eye with an ointment containing 5% potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione.

During the survey two weeks later, the cornea is transparent, rainbow clean, condition is satisfactory.

Example 4.

Patient Z., 52.

Complaints of blurred vision, cramps after suffering an eye injury caused by eye contact hydrochloric acid solution.

Turning inflammation of the cornea of both eyes, partially the second clouding with small ulcerations of the cornea of the left eye.

The diagnosis of keratitis.

A course of treatment: daily for 12 days injection:

the eye, in both eyes - a mixture of lithium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 100 mg (equal (1:1) ratio of lithium and potassium salts) in 1 ml of water for injection and intramuscular injection of a mixture (in equal proportions) sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione one dose of 200 mg in 2 ml water for injection and lubrication (3-4) times a day conjunctiva 15% eye ointment, including a mixture in equal proportions of lithium, potassium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione and dusting on the night of the cornea powder containing a mixture of potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

After the course is positive, the condition is satisfactory, the assigned eye drops containing 10% aqueous solution of a mixture of sodium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione recommended the continuation of the procedures lubrication of the conjunctiva of the eye ointment former staff and dusting of the cornea, but the corresponding potassium salt.

3 weeks after the start of treatment of the cornea clean, inflammation and ulcerations not recommended to continue for 5 days lubrication in the morning and in the evening of the conjunctiva of the eye ointment include the her 2% sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione.

Example 5.

Patient U., 64 years old.

In medical examination found partial opacity in the peripheral parts of the lens of the left eye. In addition, when reading headaches, eyes periodically “floaters.”

Diagnosis: immature cataract of the left eye, complicated by inflammation of the choroid.

A course of treatment: daily for 10 days injection:

the eye, in both eyes - a mixture of lithium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 100 mg (equal to the ratio of lithium and sodium salts) in 1 ml of water for injection and intramuscular injection of a mixture (in equal proportions) lithium, sodium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 150 mg in 2 ml water for injection and lubrication (2-3) times a day conjunctiva 15% eye ointment, comprising a mixture in equal proportions of lithium sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

After the course is positive, the field of turbidity are practically absent, the headaches stopped, the condition is satisfactory.

Assigned eye drops containing 5% aqueous solution of a mixture in equal proportions of sodium and potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, within 7 days once in the morning and also recommended the continuation of the course (7-10) days of the procedure, the greasing of the conjunctiva of the eye ointment still stock.

Example 6.

Patient C., 75 years old.

Complaints of pain in left eye, blurred vision.

History of cataract extraction, the eyes with intraocular lens implantation.

When applying the detected partial clouding of the lens of the right eye. Eye pressure in his right eye 24 in the left - 27 mm Hg

The diagnosis of primary glaucoma.

A course of treatment: daily for 10 days injection: eye, in both eyes - a mixture of lithium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 100 mg (equal to the ratio of lithium and sodium salts) in 1 ml of water for injection and intramuscular injection of a mixture (in equal proportions) lithium and sodium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione dose of 150 mg in 2 ml water for injection and instillation in the conjunctiva of each eye eye drops containing 5% aqueous solution of a mixture in equal proportions of lithium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

After the course is positive, the field of turbidity are practically absent, eye pressure in his right eye 18 in the 20 mm Hg headaches stopped, the condition is satisfactory.

Recommended continuing treatment under the old scheme.

1. The method of treatment of eye diseases, including the introduction into the conjunctival SAC of the eye of the patient medication the aqueous preparation in the form of alkaline salts, characterized in that during the treatment the rate of injection of the patient, with the introduction of the drug produce 1-5 times a day, the rate of injection contains 10-25 injections, and injections carried out 1-2 times a day or 1 time a day, and for injection using alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione, while a single dose for injection is chosen in the amount of 20-2000 mg alkaline salt or a mixture of alkaline salts of 5-Amico-2,3-dihydro-1,4-phthalazinedione 1-10 ml of water for injection.

2. The method according to claim 1, characterized in that alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione choose or lithium, or sodium, or potassium, or calcium salt and as a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione use is composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

3. The method according to claim 1 or 2, characterized in that when the drug is Reparata for introduction into the conjunctival SAC of the eyes of the patient or for injection lithium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or for injection, either lithium, or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

4. The method according to claim 1 or 2, characterized in that selecting as a medicinal product for introduction into the conjunctival SAC of the eyes of the patient or for injection of sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or incorporating into the conjunctival SAC of the eye of the patient to choose or sodium, or lithium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium is Oh salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

5. The method according to claim 1 or 2, characterized in that selecting as a medicinal product for introduction into the conjunctival SAC of the eyes of the patient or for injection of the potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or incorporating into the conjunctival SAC of the eye of the patient to choose or potassium, or lithium, or sodium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

6. The method according to claim 1 or 2, characterized in that selecting as a medicinal product for introduction into the conjunctival SAC of the eyes of the patient or for injection of the calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting or incorporating into the conjunctival SAC of the eye of the patient to choose or calcium, or lithium, or sodium, or potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, when equal zootoxin and the components of the mixture or lithium and sodium, or lithium or potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

7. The method according to any one of claims 1 to 6, characterized in that the introduction into the conjunctival SAC of the eye of the patient medication exercise and/or by putting the appropriate eye drops, or/and lubrication of the conjunctiva of the corresponding eye ointment or dusting of the cornea powder drug.

8. The method according to claim 7, characterized in that when the dusting of the cornea as drug use or lithium, or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-nafta is aindiana.

9. The method according to any one of claims 1 to 8, characterized in that when choosing or for injection or eye drops or eye ointment or dusting of the cornea to the lithium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting of the cornea, either lithium or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

10. The method according to any one of claims 1 to 8, characterized in that when choosing or for injection or eye drops or eye ointment or dusting of the cornea sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting of the cornea, either sodium or lithium, potassium, or calcium salt of 5-amino-2,3-Digi the ro-1,4-phthalazinedione or made, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

11. The method according to any one of claims 1 to 8, characterized in that when choosing or for injection or eye drops or eye ointment or dusting of the cornea of the potassium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting cornea choose or potassium, or lithium, or sodium, or calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione, or composed of, for example, equal to the ratio of the components the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

12. The method according to mu the mu one of claims 1 to 8, characterized by the fact that when choosing or for injection or eye drops or eye ointment or dusting of the cornea of the calcium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione respectively when injecting, in the part of the eye drops, in the part of the eye ointment, dusting cornea choose or calcium, or lithium, or sodium, or potassium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione or composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

13. Eye drops containing an aqueous solution of alkaline salts, characterized by the fact that they use alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione in the following ratio of components,% vol.: alkaline salt or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 0,1-10,0; water - the rest.

14. Eye drops to 13, characterized in that alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione in use with testwuide or lithium, or sodium, or potassium, or calcium salt and as a mixture of alkaline salts choose is composed of, for example, with an equal ratio of components of the mixture or lithium and sodium, or lithium, and potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.

15. Eye ointment containing pharmaceutical preparation in the form of alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione ointment on the basis of, characterized in that it also includes a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione and ointment base is made in the form, for example, medical vaseline, in the following ratio of components, wt.%: alkaline salt of 5-amino-2,3-dihydro-1,4-phthalazinedione or a mixture of alkaline salts of 5-amino-2,3-dihydro-1,4-phthalazinedione - 1,0-50,0; vaseline medical - rest.

16. Eye ointment 15, characterized in that alkali metal salts of 5-amino-2,3-dihydro-1,4-phthalazinedione it uses appropriate or lithium, or sodium, or potassium, or calcium salt and as a mixture of alkaline salts choose is composed of, for example, when equal sootnoshenie the components of the mixture or lithium and sodium, or lithium or potassium, or lithium and calcium, or sodium and potassium, or sodium and calcium, or potassium, and calcium, or lithium, sodium and potassium, or lithium, sodium and calcium, or sodium, potassium and calcium, or lithium, sodium, potassium and calcium salts of 5-amino-2,3-dihydro-1,4-phthalazinedione.



 

Same patents:

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: claimed composition contains (mass %): antiviral drug 0.001-5; vegetable and/or animal phospholipids 0.001-2; sodium chloride 0.8-0.9; sodium hydrophosphate 0.001-0.2; sodium dihydrophosphate 0.001-0.2; and balance: distilled water.

EFFECT: composition with prolonged and effective action.

3 ex

FIELD: medicine.

SUBSTANCE: method involves introducing hypotensive means by means of instillations. Eye drops of emoxipin are instilled 20-30 min later twice a day during 4-8 weeks. The treatment course is repeated in 2-3 months.

EFFECT: improved vision function; normalized hemodynamic values.

1 tbl

The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of inflammatory processes in the eyeball

The invention relates to the field of medicine

The invention relates to medicine, in particular to ophthalmology

The invention relates to medicine, in particular to ophthalmology

The invention relates to pharmaceutical industry and relates to pharmaceutical compositions containing 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, to prevent, treatment or inhibition of the development of a simple retinopathy or preproliferative retinopathy; the method of preventing, treating or inhibiting the development of a simple retinopathy or preproliferative retinopathy; and applying the 2-ethoxy-1-[[2'-(1 N-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid or 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]the benzimidazole-7-carboxylate
The invention relates to ophthalmology and is intended for the treatment of dry eye syndrome (DES) after suffering ophthalmopathy, as well as for treatment of SHBG other etiology
The invention relates to medicine, namely to ophthalmology, and can be used in the operations

The invention relates to medicine, in particular to ophthalmology

The invention relates to medicine, in particular to Oncology, urology, and can be used in the treatment of patients with advanced prostate cancer with metastatic lesions of the spine

The invention relates to medicine, surgery
The invention relates to medicine, in particular to pulmonology and concerns of conservative stopping pulmonary hemorrhage
The invention relates to the field of medicine
The invention relates to medicine and can be used in neurology, neurosonology, oral and maxillofacial surgery for the treatment of patients with trigeminal neuralgia

The invention relates to medicine, namely to the development of compositions of the solutions used during operations on the “open” heart
The invention relates to medicine, namely to dentistry, and medical concerns preparation of patients for outpatient, dental intervention
The invention relates to medicine, in particular to surgery, and can be used to stop acute gastroduodenal bleeding

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: treatment of ophthalmology diseases by administration in conjunctival sac of patient eye as well as injection of medicine, in particular alkali salt of 5-amino-2,3-dihydro-1,4-phtalasindione is disclosed. Eye drops, eye ointment contain alkali salts of 5-amino-2,3-dihydro-1,4-phtalasindione or mixture thereof, wherein lithium or sodium, or potassium, or calcium salt of 5-amino-2,3-dihydro-1,4-phtalasindione is selected as alkali salt, and mixture of above mentioned salt in equal ratio is used as mixture salts of 5-amino-2,3-dihydro-1,4-phtalasindione.

EFFECT: treatment method with improved effectiveness and reduced treatment duration.

16 cl, 6 ex

Up!